Marie Thibault from BTIG sets a price target of $103 for Edwards Lifesciences (NYSE: EW), indicating a potential increase of approximately 20.07% from its current price.The company's focus on sustainable growth and innovation in heart valve therapies and critical care monitoring positions it well for future stock performance.Edwards Lifesciences enters 2026 with strong momentum, emphasizing patient-centered approaches and leading therapies in structural heart innovations.Edwards Lifesciences (NYSE: EW) is a ...

Edwards Lifesciences (NYSE: EW) is a prominent player in the medical technology sector, specializing in heart valve therapies and critical care monitoring. The company is renowned for its innovative solutions in structural heart disease, particularly for conditions like aortic stenosis and mitral regurgitation. Edwards competes with other medical device giants, but its focus on patient-centered approaches sets it apart.On December 4, 2025, BTIG updated its rating for Edwards Lifesciences to a "Buy" recommen ...